Tesch, G
CMS is launching the Medicare GLP-1 Bridge program, which will extend coverage of certain GLP-1 medications for weight loss to eligible Medicare beneficiaries, regardless of whether they have an underlying medical condition
These tests measure your C15:0 levels, which allows you to fix nutritional C15:0 deficiencies, optimize the strength of your cells and slow the aging of your cells.
Mounjaro received NICE approval for weight management in December 2024
Those who stayed on their medications lost an average 12% body weight.Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well.People who stayed on their meds and received high doses lost nearly 14% of their body weight with semaglutide and 18% with tirzepatide.Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of health care providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions, Gasoyan said.Overall, patients had higher odds of losing 10% or more of their body weight after a year if they remained on their meds, were prescribed a high dosage, were taking tirzepatide rather than semaglutide, and were female, results show.The cost of the drugs and problems were insurance were a common reason for patients stopping GLP-1 treatment, along with side effects and medication shortages, researchers said.Staying on the GLP-1 meds particularly helped the nearly 17% of patients who had prediabetes, a condition in which elevated blood sugar levels increase a persons risk of developing type 2 diabetes.About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier.Type 2 diabetes is one of the most common complications of obesity, so diabetes prevention is very important, Gasoyan said
